Influence on Effectiveness of Early Treatment with Anti-TNF Therapy in Rheumatoid Arthritis

被引:7
|
作者
Escudero-Vilaplana, Vicente [1 ,3 ]
Ramirez-Herraiz, Esther [2 ]
Trovato-Lopez, Nicolas [1 ,3 ]
Alanon-Plaza, Estefania [2 ]
Jose Bellini, Maria [1 ,3 ]
Herranz-Alonso, Ana [1 ,3 ]
Maria Bellon-Cano, Jose [3 ]
Morell-Baladron, Alberto [2 ]
Sanjurjo-Saez, Maria [1 ,3 ]
机构
[1] Gregorio Maranon Univ, Dept Pharm, Gen Hospital, Madrid 28007, Spain
[2] La Princesa Univ, Dept Pharm, Madrid, Spain
[3] Gregorio Maranon Univ, Gen Hosp, Inst Hlth Res, Madrid, Spain
来源
关键词
GENERAL-POPULATION; CLINICAL-RESPONSE; ANTIBODIES; METHOTREXATE; ADALIMUMAB; DISABILITY; COHORT; SPAIN; COST;
D O I
10.18433/J33W30
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. To evaluate the association between starting early treatment with anti-TNF and effectiveness as well as the possibility of applying therapeutic spacing in daily practice in patients with rheumatoid arthritis (RA). Methods. Observational, retrospective study conducted in two universitary hospitals in Spain. RA patients who received the first anti-TNF (adalimumab: ADA, etanercept: ETN or infliximab: IFX) during the study period (October 2006-2010) were included. Demographic data, time since diagnosis, disease activity (DAS28-ESR) and anti-TNF dosage were analyzed. Therapeutic objective was defined as DAS28<2.6. Also the response related to criteria of the European League Against Rheumatism (EULAR) was evaluated. Therapeutic spacing was defined as the use of a lower dose or a higher interval according to label doses. The main endpoint was to assess the association between the effectiveness and the moment when the anti-TNF therapy begins. The secondary target was to evaluate the association between RA activity at the beginning of treatment with anti-TNF and dose used. Results. 82 patients were included. The prescription profile was: ADA (48.8%), ETN (31.7%) and IFX (19.5%). 71.4% of patients treated with anti-TNF during the first year since diagnosis, 57.1% of those who started after 1-5 years and 30.6% of patients who started after 5 years were in remission when the study ended. De-escalation strategy was performed in 25.6% of patients: ETN (38.5%), ADA (20.0%) and IFX (18.8%). The patients treated with a higher dose according to label doses were: IFX (81%), ADA, (12.5%) and ETN (7.7%). Conclusions. Results suggest that early treatment with anti-TNF can achieve a higher percentage of remissions. Therapeutic spacing is established as a strategy that improves the efficiency in those patients in remission, being the ETN the anti-TNF most susceptible for spacing, although a relation between the early beginning with anti-TNF and the used dose was not found.
引用
收藏
页码:355 / 360
页数:6
相关论文
共 50 条
  • [1] Anti-TNF therapy in rheumatoid arthritis
    Meyer, O
    [J]. PRESSE MEDICALE, 2000, 29 (09): : 463 - 468
  • [2] Anti-TNF Treatment in Rheumatoid Arthritis
    Geiler, Janina
    Buch, Maya
    McDermott, Michael F.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (29) : 3141 - 3154
  • [3] Influence of age on the outcome of anti-TNFα therapy in rheumatoid arthritis
    Radovits, Beata J.
    Kievit, Wietske
    Fransen, Jaap
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    van Riel, Piet L. C. M.
    Laan, Roland F. J. M.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S765 - S765
  • [4] Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis
    Rosalia Martínez-Pérez
    Julia Uceda
    Mario León
    Sergio Rodríguez
    Alejandro Muñoz
    Francisco Gallo
    Maria Luisa Velloso
    Jose Luis Marenco
    [J]. Journal of Translational Medicine, 9 (Suppl 2)
  • [5] The emerging role of anti-TNF therapy in the treatment of rheumatoid arthritis
    Lipsky, PE
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (08): : S506 - S509
  • [6] Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment
    Lazurova, Ivica
    Tomas, Lubomir
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 52 (03) : 323 - 332
  • [7] Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment
    Ivica Lazúrová
    Ľubomír Tomáš
    [J]. Clinical Reviews in Allergy & Immunology, 2017, 52 : 323 - 332
  • [8] Clinical effectiveness of anti-TNF, non-anti-TNF and tofacitinib in the treatment of rheumatoid arthritis
    Oliveira, Gerusa
    Morgado, Marina
    Brandao, Natalia
    Barreto, Jessica
    Acurcio, Francisco A.
    Guerra Junior, Augusto
    Alvares-Teodoro, Juliana
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 170 - 170
  • [9] NEUTROPENIA WITH ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS
    Litwic, Anna E.
    Tann, Maxine
    Ledingham, Joanna M.
    [J]. RHEUMATOLOGY, 2009, 48 : I68 - I68
  • [10] Anti-TNFα therapy in rheumatoid arthritis and autoimmunity
    Paola Caramaschi
    Domenico Biasi
    Marco Colombatti
    Sara Pieropan
    Nicola Martinelli
    Antonio Carletto
    Alessandro Volpe
    Luisa Maria Pacor
    Lisa Maria Bambara
    [J]. Rheumatology International, 2006, 26 : 209 - 214